Regeneron Pharmaceuticals has reported encouraging results from their Phase 1/2 clinical trial of linvoseltamab.

Vincerx Pharma, a biopharmaceutical firm, has reported encouraging preliminary results from the Phase 1 clinical trial of its drug candidate VIP236, which targets metastatic solid tumors.

May 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Clover Biopharmaceuticals, a leading biotech firm, has reported promising initial results from its Phase I clinical trial for SCB-1019, a novel bivalent RSV vaccine.

Inozyme Pharma, Inc. recently reported promising data from Phase 1/2 clinical trials of their drug INZ-701.

Cynata Therapeutics has successfully completed patient recruitment for its Phase 1 clinical trial of CYP-006TK, a treatment for diabetic foot ulcers (DFU).

The trial focused on MT-601, a novel T cell therapy targeting various tumor antigens, and was well-tolerated by participants, leading to sustained objective responses.

CytomX Therapeutics has initiated a Phase 1 clinical trial for CX-2051, an antibody drug conjugate (ADC) aimed at treating advanced solid tumors.

Oryzon Genomics, a biopharmaceutical firm specializing in epigenetic therapies for diseases with significant medical needs, has received approval from the U.S. FDA to begin a Phase I/II clinical trial.

Encouraging initial findings indicate that individuals with relapsed or refractory multiple myeloma, who experienced progression post BCMA-directed treatments, have shown clinical improvements with P-BCMA-ALLO1, demonstrating a good safety profile.

New findings reveal that zerlasiran, an innovative therapeutic developed by Silence Therapeutics plc, effectively reduces lipoprotein(a) (Lp(a)) levels and is well-tolerated in both single and multiple doses.

The Phase 1/2 KRYSTAL-1 trial, sponsored by Mirati Therapeutics, Inc., a subsidiary of Bristol Myers Squibb, combined KRAZATI® (adagrasib) with cetuximab to treat this specific group of patients who had undergone prior treatment.